Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.0029.03%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 988.50K | 1.03M | 391.50K | 990.70K | 1.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 988.50K | 1.03M | 391.50K | 990.70K | 1.80M |
| Operating Income | -988.50K | -1.03M | -391.50K | -990.70K | -1.80M |
| Income Before Tax | -955.60K | -987.00K | -336.50K | -922.70K | -2.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -955.60K | -987.00K | -336.50K | -922.70K | -2.04M |
| Earnings from Discontinued Operations | -- | -- | 0.00 | -- | 7.47M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -955.60K | -987.00K | -336.50K | -922.70K | 5.43M |
| EBIT | -988.50K | -1.03M | -391.50K | -990.70K | -1.80M |
| EBITDA | -- | -- | 316.30K | -282.90K | -1.09M |
| EPS Basic | -0.30 | -0.03 | 0.04 | -0.03 | -1.20 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.05 |
| EPS Diluted | -0.30 | -0.03 | 0.04 | -0.03 | -1.20 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.05 |
| Average Basic Shares Outstanding | 47.39M | 46.22M | 42.44M | 42.28M | 25.92M |
| Average Diluted Shares Outstanding | 47.39M | 46.22M | 42.44M | 42.28M | 25.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |